| Literature DB >> 29478670 |
Natalia Chmielewska1, Janusz Szyndler2, Karolina Makowska3, Dawid Wojtyna1, Piotr Maciejak4, Adam Płaźnik4.
Abstract
The role of blood brain barrier (BBB) is to preserve a precisely regulated environment for proper neuronal signaling. In many of the central nervous system (CNS) pathologies, the function of BBB is altered. Thus, there is a necessity to evaluate a fast, noninvasive and reliable method for monitoring of BBB condition. It seems that revealing the peripheral diagnostic biomarker whose release pattern (concentration, dynamics) will be correlated with clinical symptoms of neurological disorders offers significant hope. It could help with faster diagnosis and efficient treatment monitoring. In this review we summarize the recent data concerning exploration of potential new serum biomarkers appearing in the peripheral circulation following BBB disintegration, with an emphasis on epilepsy, traumatic brain injury (TBI) and stroke. We consider the application of well-known proteins (S100β and GFAP) as serum indicators in the light of recently obtained results. Furthermore, the utility of molecules like MMP-9, UCHL-1, neurofilaments, BDNF, and miRNA, which are newly recognized as a potential serum biomarkers, will also be discussed.Entities:
Keywords: Blood–brain barrier dysfunction; Epilepsy; Peripheral biomarker; Stroke; TBI
Mesh：
Substances：
Year: 2018 PMID： 29478670 DOI： 10.1016/j.pjnns.2018.02.002
Source DB: PubMed Journal: Neurol Neurochir Pol ISSN： 0028-3843 Impact factor: 1.621